Preface,
Jes Olesen, Stephen Silberstein and Peer Tfelt-HansenSession I - Methodology of prophylactic trials
1. Principles of preventive pharmacotherapy in primary headache, Peter J Goadsby
2. Methodology and implementation of systematic reviews, Henry J McQuay
3. Adverse events, equally important as efficacy as an outcome parameter?, Doris Irene Stenver
4. Methodology of prophylactic trials: discussion summary, Peer Tfelt-Hansen
Session II - Prophylactic drugs I
5. Key issues in the methodology of prophylactic migraine trials, Peer Tfelt-Hansen
6. Migraine prophylaxis: a pharmacoepidemiological study of practices used by general practitioners and neurologists in France, M Lanteri-Minet, H Aalchaar, G Besson, F Bille-Turc, F Brudon, A Donnet, J Valance and JL Gastaut
7. Preventive treatment of migraine headache with rofecoxib, W Hester Visser, William Malbecq, Kim Strohmaier, Christopher Lines and Scott A Reines
8. Prophylactic treatment and course of the disease in headache associated with sexual activity, Achim Frese, Katrin Frese, Sonja Schwaag, Alexandra Rahmann, Ingo-W Husstedt and Stefan Evers
9. Propylactic drugs I: discussion summary, Stephen D Silberstein
Session III - Prophylactic drugs II
10. Prevention of migraine: betablockers and amine agonists: efficacy, Hans-Christoph Diener and Volker Limmroth
11. Antiepileptic drugs in migraine prevention, Stephen D Silberstein
12. Mechanism(s) of action of the antiepileptic drugs Valproic Acid, Gabapentin, and Topiramate: implications for the prophylactic management of migraine, H Steve White
13. Experience with topiramate in patients with refractory migraine, J Pascual, M Sanchez del Rio, V Mateos, JM Lainez, J Hernandez-Gallego, R Leira and MD Jimenez
14. Topiramate in a selective group of therapy refractory headache patients, Reto M Agosti and Sonja Eugster
15. Prophylactic drugs II: discussion summary, Jean Schoenen
Session IV - Prophylactic Drugs III
16. Efficacy of antidepressants in headache prophylaxis, Lars Bendtsen
17. Antidepressants: mechanisms of action, Elliott Richelson
18. Other prophylactic anti-migraine agents: riboflavin feverfew, magnesium, botulinum toxin and calcium antagonists, Jean Schoenen, Laura Di Clemente and Gianluca Coppola
19. Treatment of chronic tension type headache with mirtazapine, Isin Baral Kulaksizoglu, Sibel Cakir and Mustafa Ertas
20. Botulinum toxin type A in the treatment of refractory headache, Stewart J Tepper, Marcelo E Bigal, Fred D Sheftell and Alan Rapoport
21. Botulinum toxin A in the prophylaxis of migraine - a double-blind, placebo-controlled, randomised study comparing frontal and cervical injection, Sonja Schwaag, Alexandra Rahmann, Achim Frese, Ingo-W Husstedt, Juliane Vollmer-Haase and Stefan Evers
22. Description of a prospective, multicenter observational study of headache treatment with Botulinum toxin type A: the program to assess treatment strategies (PATS) registry, Stephen Silberstein, M Alan Stiles, Cheryl Gebeline-Myers and Kathleen Coughlin Bradley
23. Mechanisms of the antinociceptive effect of subcutaneous BOTOX: inhibition of peripheral and central nociceptive processing, M Cui and KR Aoki
24. Survey on expenditure for analgesics in chronic tension headache and its changes following botulinum toxin type A preventive treatment, Gabriella Coloprisco, Sergio De Filippis, Pier Giorgio Santi, Guiseppe Fiore, Anna Rodio and Paolo Martelletti
25. Prophylactic treatment of migraine with lomerizine hydrochloride, Yoko Hibi, Hisaka Igarashi, Fumihiko Sakai
26. Prophylactic drugs III: discussion summary, Peter J Goadsby
Session V - New Targets I
27. Antagonising peripheral sensitisation in migraine, Sally Bolton and Celestine O'Shaughnessy
28. New possibilities for antimigraine therapy via 5HT receptors?, RG Hill, MJ Cumberbatch and DJ Williamson
29. Dihydroergotamine interaction with 5-HT receptors and its relevance to migraine, B Schaerlinger, P Hickel, N Etienne and L Maroteaux
30. Migraine prophylaxis with drugs influencing the angiotensin system, Lars Jacob Stovner, Erling Tronvik, Harald Schrader, Grethe Helde, Trond Sand and Gunnar Bovim
31. Naratriptan in the preventive treatment of refractory chronic migraine, Alan M Rapoport, Marcelo E Bigal, Stewart J Tepper, Fred D Sheftell
32. PROMISE study prophylaxis of migraine with seglor, A Pradalier, M Lanteri-Minet, Ch Lucas and G Geraud
33. Serotinin receptors and migraine prophylaxis - the case of dihydroergotamine, M Hamon, S Bourgoin and L Lanfumey
34. What is the mechanism of action of ACE inhibitors in migraine prophylaxis?, Richard Peatfeld
35. Triptans with methysergide, Dominique Valade
36. New Targets I: discussion summary, Jes Olesen
Session VI - new targets II
37. Nitric Oxide and its signalling pathways: a rich source of potential targets for migraine therapy, Paul JLM Strijbos and Andrew A Parsons
38. Calcitonin gene related peptide (CGRP), Henri Doods
39. Phosphodiesterases, cyclic nucleotides, and their role in migraine, Christina Kruuse and Joseph A Beavo
40. The prostaglandin-E-analog misoprostol in the prophylactic treatment of refractory cluster headache and trigeminal neuralgia, Stefan Evers, Achim Frese, Sonja Schwaag, Reiner Luttmann and Ingo-W Husstedt
41. New targets II: discussion summary, Ray Hill